Alpha Modus (AMOD) Chief Executive William Alessi emphasized Thursday the company's "strong" fundamentals and an "ongoing" growth strategy amid "uninformed speculation" by certain market participants.
"The recent sell-side activity targeting AMOD stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy coupled with the 'de-SPAC norm,'" Alessi said in a company statement.
Shares soared 133% as intraday trading volume surged to over 115.9 million from a daily average of about 66,000.
Tectonic Therapeutic (TECX) shares surged 109% after the company said Thursday a phase 1b trial showed that a single intravenous dose of TX45 resulted in "meaningful improvements" in left ventricular function and pulmonary hemodynamics.
Over 4.3 million shares traded intraday versus a daily average of nearly 144,000.
Alterity Therapeutics (ATHE) said Thursday its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.
Shares jumped 50% as intraday trading volume catapulted to more than 20.6 million from a daily average of about 71,000.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。